


## CLAIM AMENDMENTS

1. (currently amended): A compound according to Formula I:



wherein, W is a nitrogen atom and Y is void, or, W is a carbon atom and Y=H;


R<sup>1</sup> to R<sup>7</sup> may be the same or different and are independently hydrogen or straight, branched or cyclic C<sub>1-6</sub> alkyl;

R<sup>8</sup> is an optionally substituted heterocyclic group or an optionally substituted aromatic group

Ar is an aromatic or heteroaromatic ring optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;

n and n' are independently, 0-2;

X is a group of the formula:



wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted nitrogen atom and wherein any heteroatom in addition to P in ring A ~~or B~~ is N;

wherein Ring B is an optionally substituted 5 to 7-membered ring;

wherein Ring A or Ring B is bound to group W from any position through group V;

wherein V is a chemical bond or V is a (CH<sub>2</sub>)<sub>n''</sub> group (where n''= 1-2), or V is a C=O group; and

wherein Z is selected from the group consisting of: a hydrogen atom; an optionally substituted C<sub>1-6</sub> alkyl group; an optionally substituted aromatic or heterocyclic group; ~~a C<sub>1-6</sub> alkyl group substituted with an optionally substituted aromatic or heterocyclic group~~; an optionally substituted amino group; an optionally substituted C<sub>1-6</sub> alkylamino or C<sub>3-7</sub> cycloalkylamino group; ~~a sulfonyl group~~ and an optionally substituted carbonyl group; or

the pharmaceutically acceptable acid addition salts thereof;  
including said compound in any stereoisomeric form and any mixture of stereoisomeric forms thereof;

wherein Ring B is selected from the group consisting of: benzene and a 5 to 7-membered cycloalkyl ring; and the optionally substituted forms thereof.

2. (previously amended): The compound of claim 1, wherein Ring A is selected from the group consisting of: pyridine; pyrimidine; pyrazine; pyridazine; triazine; piperidine; piperazine; imidazole; pyrazole; and triazole and the optionally substituted forms thereof.

F<sub>1</sub>  
3. (canceled)

3A (previously amended): The compound of claim 1, wherein Ring B is selected from the group consisting of: cyclopentyl; cyclohexyl; cycloheptyl; cyclopentenyl; cyclohexenyl; and cycloheptenyl and the optionally substituted forms thereof.

5. (canceled)

4B (previously amended): The compound of claim 1, wherein Ring A and Ring B together are optionally substituted dihydroquinoline or tetrahydroquinoline.

5A (previously amended): The compound of claim 1, wherein Ring A and Ring B are independently optionally substituted with a substituent selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

8-11. (canceled)

6 12. (previously amended): The compound of claim 1 wherein said optional substituent in Ring A or Ring B is independently an optionally substituted aralkyl or

heterocycloalkyl, wherein said heterocycloalkyl is a 5 or 6 membered ring containing 1-4 heteroatoms.

<sup>7</sup>  
~~13.~~ (previously amended): The compound of claim <sup>6</sup>~~12~~, wherein said optionally substituted aralkyl or heterocycloalkyl is selected from the group consisting of: phenylC<sub>1-4</sub>alkyl; phenylmethyl (benzyl); phenethyl; pyridinylmethyl; and pyridinylethyl.

14-50. (canceled)

<sup>8</sup>  
~~51.~~ (previously amended): The compound of claim 1, wherein Z is an optionally substituted C<sub>1-6</sub>alkyl group, wherein said C<sub>1-6</sub>alkyl group is substituted with one or more substituents selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

52-54. (canceled)

<sup>9</sup>  
~~55.~~ (previously amended): The compound of claim 1, wherein Z is an optionally substituted aromatic or heterocyclic group or a C<sub>1-6</sub>alkyl group optionally substituted with an optionally substituted aromatic or heterocyclic group.

<sup>10</sup>  
~~56.~~ (previously amended): The compound of claim <sup>9</sup>~~55~~, wherein said optionally substituted aromatic group is substituted with a substituent selected from the group consisting of: benzene; naphthalene; dihydronaphthalene; and tetrahydronaphthalene; and wherein said optionally substituted heterocyclic group is a 5 to 6-membered saturated, partially saturated, or aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.

<sup>11</sup>  
~~57.~~ (original): The compound of claim <sup>10</sup>~~56~~, wherein said heterocyclic group is selected from the group consisting of: pyridine, quinoline, isoquinoline, imidazole,

benzimidazole, azabenzimidazole, benzotriazole, furan, benzofuran, thiazole, benzothiazole, oxazole, benzoxazole, pyrrole, indole, indoline, indazole, pyrrolidine, pyrrolidone, pyrroline, piperidine, piperazine, tetrahydroquinoline, tetrahydroisoquinoline, pyrazole, thiophene, isoxazole, isothiazole, triazole, tetrazole, oxadiazole, thiadiazole, morpholine, thiamorpholine, pyrazolidine, imidazolidine, imidazoline, tetrahydropyran, dihydropyran, benzopyran, dioxane, dithiane, tetrahydrofuran, tetrahydrothiophene, dihydrofuran, and dihydrothiophene.

<sup>12</sup>  
~~58.~~ (previously amended): The compound of claim <sup>11</sup>~~57~~, wherein said heterocyclic group contains nitrogen or sulfur heteroatoms; and wherein said nitrogen or sulfur heteroatoms are optionally in the form of oxides.

59-97. (canceled)

- <sup>13</sup>  
~~98.~~ (currently amended): A compound selected from the group consisting of:
- (a) AMD8862, N-(2-pyridinylmethyl)-N'-[2-[(1H-imidazol-4-ylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzene dimethanamine;
  - (b) AMD8887, N-(2-pyridinylmethyl)-N'-[2-[(1H-imidazol-2-ylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
  - (c) AMD8816, N-(2-pyridinylmethyl)-N'-[2-(phenylureido)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
  - (d) AMD8737, N-(2-pyridinylmethyl)-N'-[[N''-(n-butyl)carboxamido]methyl]-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
  - (e) AMD8739, N-(2-pyridinylmethyl)-N'-(carboxamidomethyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
  - (f) AMD8752, N-(2-pyridinylmethyl)-N'-[(N''-phenyl)carboxamidomethyl]-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
  - (g) AMD8765, N-(2-pyridinylmethyl)-N'-(carboxymethyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
  - (h) AMD8715, N-(2-pyridinylmethyl)-N'-(phenylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
  - (i) AMD8907, N-(2-pyridinylmethyl)-N'-(1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;

- (j) AMD8927, N-(2-pyridinylmethyl)-N'-(5,6-dimethyl-1*H*-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine-(hydrobromide salt);
- (k) AMD8926, N-(2-pyridinylmethyl)-N'-(5-nitro-1*H*-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (l) AMD8929, N-(2-pyridinylmethyl)-N'-[(1*H*)-5-azabenzimidazol-2-ylmethyl]-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (m) AMD8931, N-(2-pyridinylmethyl)-N-(4-phenyl-1*H*-imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (n) AMD8783, N-(2-pyridinylmethyl)-N'-[2-(2-pyridinyl)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (o) AMD8764, N-(2-pyridinylmethyl)-N'-(2-benzoxazolyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (p) AMD8780, N-(2-pyridinylmethyl)-N'-(*trans*-2-aminocyclohexyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- F (q) AMD8818, N-(2-pyridinylmethyl)-N'-(2-phenylethyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (r) AMD8829, N-(2-pyridinylmethyl)-N'-(3-phenylpropyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (s) AMD8839, N-(2-pyridinylmethyl)-N'-(*trans*-2-aminocyclopentyl)-N'-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (t) AMD8726, N-[[4-[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinoliny)-glycinamide;
- (u) AMD8738, N-[[4-[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinoliny)-(L)-alaninamide;
- (v) AMD8749, N-[[4-[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinoliny)-(L)-aspartamide;
- (w) AMD8750, N-[[4-[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinoliny)-pyrazinamide;
- (x) AMD8740, N-[[4-[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinoliny)-(L)-prolinamide;
- (y) AMD8741, N-[[4-[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinoliny)-(L)-lysineamide;

- (z) AMD8724, N-[[4-[[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-benzamide;
- (aa) AMD8725, N-[[4-[[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-picolinamide;
- (bb) AMD8713, N'-Benzyl-N-[[4-[[[(2-pyridinylmethyl) amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-urea;
- (cc) AMD8712, N'-phenyl-N-[[4-[[[(2-pyridinylmethyl) amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-urea;
- (dd) AMD8716, N-(6,7,8,9-tetrahydro-5H-cyclohepta[*bacteria*b]pyridin-9-yl)-4-[[[(2-pyridinylmethyl)amino]methyl]benzamide;
- (ee) AMD8717, N-(5,6,7,8-tetrahydro-8-quinolinyl)-4-[[[(2-pyridinylmethyl)amino]methyl]benzamide;
- (ff) AMD8634, N,N'-bis(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;
- F (gg) AMD8774, N,N'-bis(2-pyridinylmethyl)-N'-(6,7,8,9-tetrahydro-5H-cyclohepta[*bacteria*b]pyridin-9-yl)-1,4-benzenedimethanamine;
- (hh) AMD8775, N,N'-bis(2-pyridinylmethyl)-N'-(6,7-dihydro-5H-cyclopenta[*bacteria*b]pyridin-7-yl)-1,4-benzenedimethanamine;
- (ii) AMD8819, N,N'-bis(2-pyridinylmethyl)-N'-(1,2,3,4-tetrahydro-1-naphthalenyl)-1,4-benzenedimethanamine;
- (jj) AMD8768, N,N'-bis(2-pyridinylmethyl)-N'-[(5,6,7,8-tetrahydro-8-quinolinyl)methyl]-1,4-benzenedimethanamine;
- (kk) AMD8767, N,N'-bis(2-pyridinylmethyl)-N'[(6,7-dihydro-5H-cyclopenta[*bacteria*b]pyridin-7-yl)methyl]-1,4-benzenedimethanamine;
- (ll) AMD8838, N-(2-pyridinylmethyl)-N-(2-methoxyethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;
- (mm) AMD8871, N-(2-pyridinylmethyl)-N-[2-(4-methoxyphenyl)ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;
- (nn) AMD8844, N,N'-bis(2-pyridinylmethyl)-1,4-(5,6,7,8-tetrahydro-8-quinolinyl)benzenedimethanamine;
- (oo) AMD7129, N-[(2,3-dimethoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine;


- (pp) AMD7130, N,N'-bis(2-pyridinylmethyl)-N-[1-(N''-phenyl-N''-methylureido)-4-piperidinyl]-1,3-benzenedimethanamine;
- (qq) AMD7131, N,N'-bis(2-pyridinylmethyl)-N-[N''-p-toluenesulfonylphenylalanyl]-4-piperidinyl]-1,3-benzenedimethanamine;
- (rr) AMD7136, N,N'-bis(2-pyridinylmethyl)-N-[1-[3-(2-chlorophenyl)-5-methyl-isoxazol-4-oyl]-4-piperidinyl]-1,3-benzenedimethanamine;
- (ss) AMD7138, N-[(2-hydroxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~baetaria~~]pyridin-9-yl)-1,4-benzenedimethanamine;
- (tt) AMD7140, N-[(4-cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~baetaria~~]pyridin-9-yl)-1,4-benzenedimethanamine;
- (uu) AMD7141, N-[(4-cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- F<sub>1</sub> (vv) AMD7142, N-[(4-acetamidophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinoliny)-1,4-benzenedimethanamine;
- (ww) AMD7145, N-[(4-phenoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~baetaria~~]pyridin-9-yl)-1,4-benzenedimethanamine;
- (xx) AMD7147, N-[(1-methyl-2-carboxamido)ethyl]-N,N'-bis(2-pyridinylmethyl)-1,3-benzenedimethanamine;
- (yy) AMD7151, N-[(4-benzyloxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~baetaria~~]pyridin-9-yl)-1,4-benzenedimethanamine; and
- (zz) AMD7155, N-[(thiophene-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[~~baetaria~~]pyridin-9-yl)-1,4-benzenedimethanamine.

99-101. (canceled)

<sup>14</sup>  
~~102.~~ (previously amended): A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 in admixture with at least one pharmaceutically acceptable excipient.

103-118. (canceled)

15  
119. (previously added; currently amended): A compound of the formula



wherein, W is a nitrogen atom and Y is void;


R<sup>1</sup> to R<sup>7</sup> may be the same or different and are independently hydrogen or straight, branched or cyclic C<sub>1-6</sub> alkyl;

R<sup>8</sup> is an optionally substituted heterocyclic group or an optionally substituted aromatic group

Ar is an aromatic or heteroaromatic ring optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;

n and n' are independently, 0-2;

X is a group of the formula:



wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted nitrogen atom and wherein any heteroatom in ring A or B is N;

wherein Ring B is an optionally substituted 5 to 7-membered ring;

wherein Ring A or Ring B is bound to group W from any position through group V;

wherein V is a chemical bond or V is a (CH<sub>2</sub>)<sub>n''</sub> group (where n'' = 1-2), or V is a C=O group; and



wherein Z is selected from the group consisting of: a hydrogen atom; an optionally substituted C<sub>1-6</sub> alkyl group; an optionally substituted aromatic or heterocyclic group; ~~a C<sub>1-6</sub> alkyl group substituted with an optionally substituted aromatic or heterocyclic group~~; an optionally substituted amino group; an optionally substituted C<sub>1-6</sub> alkylamino or C<sub>3-7</sub> cycloalkylamino group; ~~a sulfonyl group~~ and an optionally substituted carbonyl group; or the pharmaceutically acceptable acid addition salts thereof;

including said compound in any stereoisomeric form and any mixture of stereoisomeric forms thereof.

<sup>16</sup>  
~~120.~~ (previously added): The compound of claim <sup>15</sup>~~119~~, wherein Ring A is selected from the group consisting of: pyridine; pyrimidine; pyrazine; pyridazine; triazine; piperidine; piperazine; imidazole; pyrazole; and triazole and the optionally substituted forms thereof.

F, <sup>17</sup>  
~~121.~~ (previously added): The compound of claim <sup>15</sup>~~119~~, wherein Ring B is selected from the group consisting of: benzene and a 5 to 7-membered cycloalkyl ring; and the optionally substituted forms thereof.

<sup>18</sup>  
~~122.~~ (previously added): The compound of claim <sup>15</sup>~~119~~, wherein Ring B is selected from the group consisting of: cyclopentyl; cyclohexyl; cycloheptyl; cyclopentenyl; cyclohexenyl; and cycloheptenyl and the optionally substituted forms thereof.

<sup>19</sup>  
~~123.~~ (previously added): The compound of claim <sup>15</sup>~~119~~, wherein Ring A and Ring B together are optionally substituted dihydroquinoline or tetrahydroquinoline.

<sup>20</sup>  
~~124.~~ (previously added): The compound of claim <sup>15</sup>~~119~~, wherein Ring A and Ring B are independently optionally substituted with a substituent selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

<sup>24</sup>  
~~125.~~ (previously added; previously amended): The compound of claim ~~119~~<sup>15</sup> wherein said optional substituent in Ring A or Ring B is independently an optionally substituted aralkyl or heterocycloalkyl, wherein said heterocycloalkyl is a 5 or 6 membered ring containing 1-4 heteroatoms.

<sup>22</sup>  
~~126.~~ (previously added): The compound of claim ~~125~~<sup>21</sup>, wherein said optionally substituted aralkyl or heterocycloalkyl is selected from the group consisting of: phenylC<sub>1-4</sub>alkyl; phenylmethyl (benzyl); phenethyl; pyridinylmethyl; and pyridinylethyl.

<sup>23</sup>  
~~127.~~ (previously added): The compound of claim ~~119~~<sup>15</sup>, wherein Z is an optionally substituted C<sub>1-6</sub>alkyl group, wherein said C<sub>1-6</sub>alkyl group is substituted with one or more substituents selected from the group consisting of: halogen; nitro; cyano; carboxylic acid; an optionally substituted alkyl, alkenyl or cycloalkyl group; an optionally substituted hydroxyl group; an optionally substituted thiol group; an optionally substituted amino or acyl group; an optionally substituted carboxylate, carboxamide or sulfonamide group; and an optionally substituted aromatic or heterocyclic group.

<sup>24</sup>  
~~128.~~ (previously added): The compound of claim ~~119~~<sup>15</sup>, wherein Z is an optionally substituted aromatic or heterocyclic group or a C<sub>1-6</sub>alkyl group optionally substituted with an optionally substituted aromatic or heterocyclic group.

<sup>25</sup>  
~~129.~~ (previously added; previously amended): The compound of claim ~~128~~<sup>24</sup>, wherein said optionally substituted aromatic group is substituted with a substituent selected from the group consisting of: benzene; naphthalene; dihydronaphthalene; and tetrahydronaphthalene; and wherein said optionally substituted heterocyclic group is a 5 to 6-membered saturated, partially saturated, or aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.

<sup>26</sup>  
~~130.~~ (previously added): The compound of claim ~~129~~<sup>25</sup>, wherein said heterocyclic group is selected from the group consisting of: pyridine, quinoline, isoquinoline, imidazole, benzimidazole, azabenzimidazole, benzotriazole, furan, benzofuran, thiazole, benzothiazole; oxazole, benzoxazole, pyrrole, indole, indoline, indazole, pyrrolidine, pyrrolidone, pyrroline,

piperidine, piperazine, tetrahydroquinoline, tetrahydroisoquinoline, pyrazole, thiophene, isoxazole, isothiazole, triazole, tetrazole, oxadiazole, thiadiazole, morpholine, thiamorpholine, pyrazolidine, imidazolidine, imidazoline, tetrahydropyran, dihydropyran, benzopyran, dioxane, dithiane, tetrahydrofuran, tetrahydrothiophene, dihydrofuran, and dihydrothiophene.

<sup>27</sup>  
~~131~~. (previously added; previously amended): The compound of claim <sup>26</sup>~~130~~, wherein said heterocyclic group contains nitrogen or sulfur heteroatoms; and wherein said nitrogen or sulfur heteroatoms are optionally in the form of oxides.

<sup>28</sup>  
~~132~~. (previously added): A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim <sup>15</sup>~~119~~ in admixture with at least one pharmaceutically acceptable excipient.

<sup>29</sup>  
~~133~~. (new): The compound of claim 1, wherein Z is a C<sub>1-6</sub> alkyl group substituted with an optionally substituted aromatic or heterocyclic group.

<sup>30</sup>  
~~134~~. (new): The compound of claim <sup>15</sup>~~119~~, wherein Z is a C<sub>1-6</sub> alkyl group substituted with an optionally substituted aromatic or heterocyclic group.

---

## SPECIFICATION AMENDMENT

Please replace the paragraph on page 7, line 24, with the following rewritten

paragraph:

F2

~~Fig. 1~~ Fig. 1A-BBB show structural formulas of compounds of the present invention.